Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement.

ABSTRACT:

Objectives/hypothesis

The purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality.

Study design

Delphi method-based survey series.

Methods

A multidisciplinary, multi-institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains: 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work-up.

SUBMITTER: Sidell DR 

PROVIDER: S-EPMC9034687 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature